Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of MaaT013 as salvage therapy in ruxolitinib-refractory gastrointestinal acute graft-versus-host disease
2021-001841-11Phase 3Active
- Sponsor
- MaaT Pharma
- Start
- Aug 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of MaaT013 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by MaaT Pharma. Primary endpoint: Overall response rate of gastrointestinal acute graft-versus-host disease at day 28. Started Aug 2021; status: active.
02
Drugs
MaaT013
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2021-001841-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001841-11.